2025-2026 Regular Session
HF4852
Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.
Legislative progress
i
This summary includes only completed milestones supported by recorded actions. It does not predict the next step, and it preserves later committee reassignments, concurrence, conference, veto, and approval actions when they occur.
Introduced in House April 7, 2026
Committee referrals
April 7, 2026 · House
Health Finance & Policy
Instrument history
i
This is the complete recorded action history in the current source package. Highlighted entries are marked as significant by the source. A roll-call link appears only when a vote-like action has one unambiguous same-day chamber vote.
-
House Introduction and first reading, referred to Health Finance and Policy